Literature DB >> 33880756

Planning and Conducting a Pharmacogenetics Association Study.

Daniel L Hertz1, Meghan J Arwood2, Gabriele Stocco3, Sonal Singh4, Jason H Karnes5,6, Laura Ramsey7.   

Abstract

Pharmacogenetics (PGx) association studies are used to discover, replicate, and validate the association between an inherited genotype and a treatment outcome. The objective of this tutorial is to provide trainees and novice PGx researchers with an overview of the major decisions that need to be made when designing and conducting a PGx association study. The first critical decision is to determine whether the objective of the study is discovery, replication, or validation. Next, the researcher must identify a patient cohort that has all of the data necessary to conduct the intended analysis. Then, the investigator must select and define the treatment outcome, or phenotype, that will be analyzed. Next, the investigator must determine what genotyping approach and genetic data will be included in the analysis. Finally, the association between the genotype and phenotype is tested using some statistical analysis methodology. This tutorial is divided into 5 sections, each section describes commonly used approaches and provides suggestions and resources for designing and conducting a PGx association study. Successful PGx association studies are necessary to discover and validate associations between inherited genetic variation and treatment outcomes, which enable clinical translation to improve efficacy and reduce toxicity of treatment. This article is protected by copyright. All rights reserved.

Entities:  

Year:  2021        PMID: 33880756     DOI: 10.1002/cpt.2270

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  1 in total

1.  Tutorial: Statistical analysis and reporting of clinical pharmacokinetic studies.

Authors:  Ann-Cathrine Dalgård Dunvald; Ditte Bork Iversen; Andreas Ludvig Ohm Svendsen; Katrine Agergaard; Ida Berglund Kuhlmann; Christina Mortensen; Nanna Elman Andersen; Erkka Järvinen; Tore Bjerregaard Stage
Journal:  Clin Transl Sci       Date:  2022-06-01       Impact factor: 4.438

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.